

PRODUCT INFORMATION



C-02

Item No. 39384

CAS Registry No.: 3033812-84-6

Formal Name: 1-[(2,4-dichlorophenyl)methyl]-N-[4-[[2-(2,6-dioxo-3-piperidiny)-2,3-dihydro-1,3-dioxo-1H-indol-4-yl]<wbr/>amino]butyl]-1H-indazole-3-carboxamide

MF: C₃₂H₂₈Cl₂N₆O₅


FW: 647.5

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥3 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

C-02 is supplied as a solid. A stock solution may be made by dissolving the C-02 in the solvent of choice, which should be purged with an inert gas. C-02 is soluble in ethanol and methanol.

Description

C-02 is a proteolysis-targeting chimera (PROTAC) composed of the hexokinase inhibitor lonidamine (Item No. 14640) linked to the cereblon ligand thalidomide (Item No. 14610).¹ It induces degradation of hexokinase 2 in 786-O and PANC-1 cells when used at a concentration of 20 μM. C-02 is cytotoxic to 786-O, 4T1, PANC-1, HGC-27, and MCF-7 cancer cells (IC₅₀s = 34.07, 5.08, 31.53, 6.11, and 21.65 μM, respectively). It reduces the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) in 4T1 cells, indicating inhibition of glycolysis and mitochondrial damage, respectively, when used at a concentration of 20 μM. *In vivo*, C-02 (50 mg/kg) reduces tumor volume and induces intratumoral cytokine accumulation and pyroptosis in a 4T1 murine mammary carcinoma model.

Reference

1. Sang, R., Fan, R., Deng, A., *et al.* Degradation of hexokinase 2 blocks glycolysis and induces GSDME-dependent pyroptosis to amplify immunogenic cell death for breast cancer therapy. *J. Med. Chem.* **66**(13), 8464-8483 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/03/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM